Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension 1998 Jan; 31(1):68-72.
Relationship between central sympathetic activity and stages of human hypertension. Am J Hypertens 2004 Mar;17(3):217-222.
Arterial plasma norepinephrine correlates to blood pressure in middle-aged men with sustained essential hypertension. Am Heart J 1989 Oct;118(4):775-781.
Renal nerves in the pathogenesis of hypertension in experimental animals and humans. Am J Physiol 1983 Jul;245(1):F1-14.
Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009 Aug;361(9):932-934.
Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension. Hypertension 2013 Feb;61(2):457-464.
Renal denervation: a potential new treatment for severe hypertension. Clin Cardiol 2013;36(1):10-14.
Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009 Apr;373(9671):1275-1281.
Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet 2014 Feb;383(9917):622-629.
Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010 Dec;376(9756):1903-1909.
Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial. Eur Heart J 2014 Jul;35(26):1752-1759.
A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014 Apr;370(15):1393-1401.
12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. J Am Coll Cardiol 2015 Apr;65(13):1314-1321.
Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J 2015 Jan;36(4):219-227.
Catheter-based radiorefrequency renal denervation lowers blood pressure in obese hypertensive dogs. Am J Hypertens 2014 Oct;27(10):1285-1292.
Catheter-based renal denervation is no simple matter: lessons to be learned from our anatomy? J Am Coll Cardiol 2014 Aug;64(7):644-646.
Anatomic assessment of sympathetic peri-arterial renal nerves in man. J Am College Cardiol 2014 Aug;64(7):635-643.
Hyperresponders vs nonresponder patients after renal denervation: Do they differ? J Hypertens 2014 Dec;32(12):2422-2427;discussion 2427.
Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension. Hypertension 2015 Mar;65(6):1202-1208.
Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet 2015 May 16;385(9981): 1957-1965.
Reduced effect of percutaneous renal denervation on blood pressure in patients with isolated systolic hypertension. Hypertension 2015 Jan;65(1):193-199.
First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension. Hypertension 2015 Apr;65(4):766-774.
4a.01: Long-term effects of renal artery denervation in real world patients with uncontrolled hypertension from the global symplicity registry. J Hypertens 2015 Jun;33(Suppl 1):e49.
Iatrogenic renal artery stenosis after renal sympathetic denervation. Int J Cardiol 2014 Apr;172(3):e389-390.
Bilateral renal artery stenosis after renal denervation. Hypertension 2014 May;63(5):e126-127.
Renal artery stenosis after renal sympathetic denervation. J Am Coll Cardiol 2012 Dec;60(25):2694-2695.
New approaches in the treatment of hypertension. Circulation Res 2015;116(6):1074-1095.
The SPYRAL HTN Global Clinical Trial Program: rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of anti-hypertensive medications. Am Heart J 2016 Jan;171(1):82-91.
Ethanol-mediated perivascular renal sympathetic denervation: Preclinical validation of safety and efficacy in a porcine model. Euro Intervention 2013 May;9(1):140-147.
Transcatheter alcohol-mediated perivascular renal denervation with the peregrine system: first-in-human experience. JACC Cardiovasc Interv 2016 Mar;9(6):589-598.
Noninvasive renal sympathetic denervation by extracorporeal high-intensity focused ultrasound in a pre-clinical canine model. J Am Coll Cardiol 2013 May;61(21):2185-2192.
Noninvasive renal denervation for resistant hypertension using high-intensity focused ultrasound. Hypertension 2015 Oct;66(4):e22-25.
Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol 2010 Oct;56(15):1254-1258.
Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol 2011 Aug;58(7):765-773.
Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. J Am Soc Hypertens 2012 Jul-Aug;6(4):270-276.
Bilateral or unilateral stimulation for baroreflex activation therapy. Hypertension 2015 Jan;65(1):187-192.
Creation of an iliac arteriovenous shunt lowers blood pressure in chronic obstructive pulmonary disease patients with hypertension. J Vasc Surg 2014 Apr;59(4):1078-1083.
Arteriovenous anastomosis: is this the way to control hypertension? Hypertension 2014 Jul;64(1):6-12.
Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): a randomised controlled trial. Lancet 2015 Apr;385(9978):1634-1641.